Association of plasmacytoid dendritic cells with B cell infiltration in minor salivary glands in patients with Sjögren's syndrome

Modern Rheumatology

Volumn 26, Issue 5, 2016, Pages 716-724

  Zhao, Jidong ^a   Kubo, Satoshi ^a   Nakayamada, Shingo ^a   Shimajiri, Shohei ^a   Zhang, Xiangmei ^a   Yamaoka, Kunihiro ^b   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

B cells; CXCL13; Macrophages; Plasmacytoid dendritic cells; Sjogren s syndrome

Indexed keywords

ALPHA INTERFERON; CD19 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CHEMOKINE RECEPTOR CXCR5; CXCL13 CHEMOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; THROMBOCYTE FACTOR 4; TUMOR NECROSIS FACTOR; AUTOANTIBODY; CXCL13 PROTEIN, HUMAN;

ACINAR CELL; ADULT; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG FIBROSIS; LYMPHOCYTIC INFILTRATION; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SALIVARY GLAND BIOPSY; SIALOADENITIS; SJOEGREN SYNDROME; AGED; DENDRITIC CELL; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; METABOLISM; MIDDLE AGED; MINOR SALIVA GLAND; PATHOLOGY;

AGED; AUTOANTIBODIES; B-LYMPHOCYTES; CHEMOKINE CXCL13; DENDRITIC CELLS; FEMALE; HUMANS; INFLAMMATION; MACROPHAGES; MIDDLE AGED; SALIVARY GLANDS, MINOR; SJOGREN'S SYNDROME;

EID: 84958551926     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2015.1129694     Document Type: Article

References (38)

1. R.I.Fox Sjogren's syndrome. Lancet. 2005;366(9482):321–31.
2. G.Nordmark, G.V.Alm, L.Ronnblom Mechanisms of disease:primary Sjogren's syndrome and the type I interferon system. Nat Clin Pract Rheumatol. 2006;2(5):262–9.
3. M.Bombardieri, C.Pitzalis Ectopic lymphoid neogenesis and lymphoid chemokines in Sjogren's syndrome:at the interplay between chronic inflammation, autoimmunity and lymphomagenesis. Curr Pharm Biotechnol. 2012;13(10):1989–96.
4. J.S.Greenspan, T.E.Daniels, N.Talal, R.A.Sylvester The histopathology of Sjogren's syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol. 1974;37(2):217–29.
5. T.Hikichi, A.Yoshida, K.Tsubota Lymphocytic infiltration of the conjunctiva and the salivary gland in Sjogren's syndrome. Arch Ophthalmol. 1993;111(1):21–2.
6. K.Yoshimoto, M.Tanaka, M.Kojima, Y.Setoyama, H.Kameda, K.Suzuki, et al. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjogren's syndrome. Arthritis Res Ther. 2011;13(5):R170.
7. P.Szodoray, G.Papp, I.F.Horvath, S.Barath, S.Sipka, B.Nakken, et al. Cells with regulatory function of the innate and adaptive immune system in primary Sjogren's syndrome. Clin Exp Immunol. 2009;157(3):343–9.
8. M.Ramos-Casals, P.Brito-Zeron, A.Siso-Almirall, X.Bosch, A.G.Tzioufas Topical and systemic medications for the treatment of primary Sjogren's syndrome. Nat Rev Rheumatol. 2012;8(7):399–411.
9. M.Ramos-Casals, A.G.Tzioufas, J.Font Primary Sjogren's syndrome:new clinical and therapeutic concepts. Ann Rheum Dis. 2005;64(3):347–54.
10. M.Ramos-Casals, P.Brito-Zeron, A.Siso-Almirall, X.Bosch Primary Sjogren syndrome. BMJ. 2012;344:e3821.
11. F.Carubbi, P.Cipriani, A.Marrelli, P.Benedetto, P.Ruscitti, O.Berardicurti, et al. Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome:a prospective, multi-center, follow-up study. Arthritis Res Ther. 2013;15(5):R172.
12. P.M.Meiners, A.Vissink, F.G.Kroese, F.K.Spijkervet, N.S.Smitt-Kamminga, W.H.Abdulahad, et al. Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis. 2014;73(7):1393–6.
13. P.R.Sada, D.Isenberg, C.Ciurtin Biologic treatment in SS. Rheumatology (Oxford). 2015;54(2):219–30.
14. S.Sugai, Y.Masaki Current and prospective treatment options for Sjogren's syndrome. Expert Rev Clin Immunol. 2008;4(4):469–79.
15. T.E.Daniels, D.Cox, C.H.Shiboski, M.Schiodt, A.Wu, H.Lanfranchi, et al. Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjogren's syndrome among 1,726 registry participants. Arthritis Rheum. 2011;63(7):2021–30.
16. S.Nakayamada, T.Fujimoto, A.Nonomura, K.Saito, S.Nakamura, Y.Tanaka Usefulness of initial histological features for stratifying Sjogren's syndrome responders to mizoribine therapy. Rheumatology (Oxford). 2009;48(10):1279–82.
17. U.Bave, G.Nordmark, T.Lovgren, J.Ronnelid, S.Cajander, M.L.Eloranta, et al. Activation of the type I interferon system in primary Sjogren's syndrome:a possible etiopathogenic mechanism. Arthritis Rheum. 2005;52(4):1185–95.
18. E.Wakamatsu, Y.Nakamura, I.Matsumoto, D.Goto, S.Ito, A.Tsutsumi, et al. DNA microarray analysis of labial salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis. 2007;66(6):844–5.
19. M.Voulgarelis, A.G.Tzioufas Pathogenetic mechanisms in the initiation and perpetuation of Sjogren's syndrome. Nat Rev Rheumatol. 2010;6(9):529–37.
20. G.Hernandez-Molina, M.Michel-Peregrina, D.F.Hernandez-Ramirez, J.Sanchez-Guerrero, L.Llorente Chemokine saliva levels in patients with primary Sjogren's syndrome, associated Sjogren's syndrome, pre-clinical Sjogren's syndrome and systemic autoimmune diseases. Rheumatology (Oxford). 2011;50(7):1288–92.
21. H.S.Carlsen, E.S.Baekkevold, H.C.Morton, G.Haraldsen, P.Brandtzaeg Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood. 2004;104(10):3021–7.
22. A.Iwasa, R.Arakaki, N.Honma, A.Ushio, A.Yamada, T.Kondo, et al. Aromatase controls Sjogren syndrome-like lesions through monocyte chemotactic protein-1 in target organ and adipose tissue-associated macrophages. Am J Pathol. 2015;185(1):151–61.
23. G.Lindahl, E.Hedfors Labial salivary gland lymphocytic infiltration in Sjogren's syndrome. Arthritis Rheum. 1991;34(8):1070–1.
24. E.Mebouta-Nkamgueu, J.J.Adnet, D.Ittelet, D.Laurent-Maquin, S.Bouthors, G.Potron, et al. Human monocyte-derived macrophages and dendritic cells as targets for biomaterial cytocompatibility studies using an improved in vitro culture system. J Mater Sci Mater Med. 2001;12(4):351–7.
25. A.Hansen, P.E.Lipsky, T.Dorner B cells in Sjogren's syndrome:indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther. 2007;9(4):218.
26. D.F.Legler, M.Loetscher, R.S.Roos, I.Clark-Lewis, M.Baggiolini, B.Moser B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med. 1998;187(4):655–60.
27. P.Perrier, F.O.Martinez, M.Locati, G.Bianchi, M.Nebuloni, G.Vago, et al. Distinct transcriptional programs activated by interleukin-10 with or without lipopolysaccharide in dendritic cells:induction of the B cell-activating chemokine, CXC chemokine ligand 13. J Immunol. 2004;172(11):7031–42.
28. G.Nordmark, M.L.Eloranta, L.Ronnblom Primary Sjogren's syndrome and the type I interferon system. Curr Pharm Biotechnol. 2012;13(10):2054–62.
29. M.E.Wildenberg, C.G.van Helden-Meeuwsen, J.P.van de Merwe, H.A.Drexhage, M.A.Versnel Systemic increase in type I interferon activity in Sjogren's syndrome:a putative role for plasmacytoid dendritic cells. Eur J Immunol. 2008;38(7):2024–33.
30. J.E.Gottenberg, N.Cagnard, C.Lucchesi, F.Letourneur, S.Mistou, T.Lazure, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA. 2006;103(8):2770–5.
31. O.Kimoto, J.Sawada, K.Shimoyama, D.Suzuki, S.Nakamura, H.Hayashi, et al. Activation of the interferon pathway in peripheral blood of patients with Sjogren's syndrome. J Rheumatol. 2011;38(2):310–16.
32. K.Tateda, S.Okazaki, S.Nagoya, R.Katada, K.Mizuo, S.Watanabe, et al. The suppression of TRIM21 and the accumulation of IFN-alpha play crucial roles in the pathogenesis of osteonecrosis of the femoral head. Lab Invest. 2012;92(9):1318–29.
33. K.McKenna, A.S.Beignon, N.Bhardwaj Plasmacytoid dendritic cells:linking innate and adaptive immunity. J Virol. 2005;79(1):17–27.
34. Z.Zhang, F.S.Wang Plasmacytoid dendritic cells act as the most competent cell type in linking antiviral innate and adaptive immune responses. Cell Mol Immunol. 2005;2(6):411–17.
35. M.Colonna, G.Trinchieri, Y.J.Liu Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004;5(12):1219–26.
36. I.Matsumoto, S.Okada, K.Kuroda, I.Iwamoto, Y.Saito, T.Tokuhisa, et al. Single cell analysis of T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. Int J Mol Med. 1999;4(5):519–27.
37. T.Maehara, M.Moriyama, H.Nakashima, K.Miyake, J.N.Hayashida, A.Tanaka, et al. Interleukin-21 contributes to germinal centre formation and immunoglobulin G4 production in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz's disease. Ann Rheum Dis. 2012;71(12):2011–19.
38. C.P.Mavragani, H.M.Moutsopoulos The geoepidemiology of Sjogren's syndrome. Autoimmun Rev. 2010;9(5):A305–10.